A biodegradable intra articular injection for patients with knee osteoarthritis
KioMedinevsone is a biodegradable intra‑articular fluid implant indicated for the symptomatic treatment of knee osteoarthritis. Delivered as a single injection, it is based on a world‑first, patented, animal‑free Carboxymethyl‑Chitosan (CM‑Chitosan) technology developed by KioMed Pharma.
Enquire now
It’s a single intra articular injection that’s Biodegradable, non animal derived formulation. It’s designed to enhance joint lubrication and supports reduction of oxidative stress in the joint environment.
KioMedinevsone is based on patented CM Chitosan, a highly purified polysaccharide derived from Agaricus bisporus (button mushroom). Due to its unique molecular structure, CM Chitosan provides KioMedinevsone with a dual mechanism of action of: Enhancement of joint lubrication and protection against oxidative stress.
KioMedinevsone is indicated for the symptomatic treatment of knee osteoarthritis in adult patients, administered as a single intra articular injection.
KioMedinevsone is manufactured by KioMed Pharma (Belgium) using patented technology. Hospital Innovations UK is the exclusive distributor of KioMedinevsone within the United Kingdom.
No. KioMedinevsone does not contain hyaluronic acid. It is based on a patented Carboxymethyl Chitosan technology.
KioMedinevsone is designed to be administered as a single intra articular injection.
No. The CM Chitosan used in KioMedinevsone is derived from Agaricus bisporus (button mushroom) and is animal free.
Hospital Innovations UK is the exclusive UK distributor of KioMedinevsone.
Learn More
Learn More
Hospital Innovations Limited is a Sponsor of the National Ligament Registry